Methods:

The mid-term follow-up data were reported among 31 patients from the LEADLESS trial who underwent implantation of a novel leadless pacemaker for symptomatic bradycardia. The device encompasses both the pacing/sensing electrode and battery (total volume, 1 cc; estimated battery longevity, 9 years), and is implanted in the septal aspect of the right ventricular apex via the femoral vein. The median implant time was 24 minutes. About one-third of the patients required repositioning during the original procedure. Two patients who had also undergone the procedure were not included: one experienced cardiac perforation and required cardiac surgery, but died several days later following a stroke; and another in whom the device was explanted due to new indication for an implantable defibrillator. Rate-response (driven by changes in blood temperature) function was also described.